 CAMBRIDGE, Mass., Aug. 04, 2020 GLOBE NEWSWIRE -- Mersana Therapeutics, Inc. NASDAQ:MRSN, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ADCs targeting cancers in areas of high unmet medical need, today announced that management will present at two upcoming investor conferences. Details are as follows: BTIG Virtual Biotechnology Conference 2020 Forum: Fireside Chat DateTime: Tuesday, August 11, 2020, at 1:00 p.m. ET2020 Wedbush PacGrow Healthcare Virtual Conference Forum: Presentation DateTime: Wednesday, August 12, 2020, at 1:45 p.m. ETA live webcast of the presentations will be available on the Investors Media section of Mersanas website at Archived replays will be available for approximately 90 days following the presentation.About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersanas lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersanas second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersanas customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING agonist ADC developed using the Companys Immunosynthen platform. In addition, multiple partners are using Mersanas Dolaflexin platform to advance their ADC pipelines.Contact:Investor Media Contact Sarah Carmody 617-844-8577 